Gilead Sciences

GILD NASDAQ
65.04
-2.17
-3.23%
After Hours: 65.10 +0.06 +0.09% 19:56 07/19 EDT
Open
67.52
Prev Close
67.21
High
67.53
Low
64.91
Volume
8.88M
Avg Vol (3M)
6.42M
52 Week High
79.61
52 Week Low
60.32
% Turnover
0.70%
Market Cap
82.70B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Gilead Sciences GILD stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
MORE >

Recently

Name
Price
%Change